ReviewDeutsches Arzteblatt international2015
Treatment Options for Statin-Associated Muscle Symptoms.
Review in Deutsches Arzteblatt international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].Schmerz (Berlin, Germany) · 2017Pooled it
- Diagnosis and Management of Statin-Associated Muscle Symptoms.Korean circulation journal · 2025Review
- Prolonged Low-Dose Administration of FDA-Approved Drugs for Non-Cancer Conditions: A Review of Potential Targets in Cancer Cells.International journal of molecular sciences · 2025Review
- Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry.American journal of preventive cardiology · 2025Article
- Determining cost-saving risk thresholds for statin use.PloS one · 2025Article
- Non adherence to lipid-lowering therapy and strategies to improve adherence.Indian heart journal · 2024Review
- [Statin intolerance-Statin tolerance].Innere Medizin (Heidelberg, Germany) · 2023Review
- Current Insights on Dyslipidaemia Management for Prevention of Atherosclerotic Cardiovascular Disease: A Malaysian Perspective.The Malaysian journal of medical sciences : MJMS · 2023Review
- [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]Innere Medizin (Heidelberg, Germany) · 2022Review
- Article
- Statin-Induced Immune-Mediated Necrotizing Myopathy Does Not Always Present With Immediate or Severe Symptoms.Journal of clinical neurology (Seoul, Korea) · 2022Article
- Review
- [State of the Art: Statin Therapy].Deutsche medizinische Wochenschrift (1946) · 2022Review
- The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.Journal of general internal medicine · 2021Observational
- [Diagnostics and treatment of statin-associated muscle symptoms].Der Internist · 2021Review
- [ESC guidelines on sports cardiology 2020 : Which sports can be performed with heart diseases?]Herz · 2021Review
- PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Observational
- Cardiovascular Risk and Statin Therapy Considerations in Women.Diagnostics (Basel, Switzerland) · 2020Review
- Kefir peptides alleviate high-fat diet-induced atherosclerosis by attenuating macrophage accumulation and oxidative stress in ApoE knockout mice.Scientific reports · 2020Article
- Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.Nanoscale · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbout 4.6 million persons in Germany are now taking statins, i.e., drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase. Statins lower the concentration of low-density lipoproteins (LDL) and thereby lessen the rate of cardiovascular events; the size of this effect depends on the extent of lowering of the LDL cholesterol concentration. Muscle symptoms are a clinically relevant side effect of statin treatment.
methodsThis review is based on pertinent publications retrieved by a selective literature search, and on the current recommendations of the European Atherosclerosis Society.
resultsAt least 5% of patients taking statins have statin-associated muscle symptoms (SAMS). The etiology of SAMS is heterogeneous. SAMS may seriously impair quality of life and cause complications of variable severity, up to and including rhabdomyolysis (in about 1 in 100,000 cases). SAMS often lead to a reduction in the prescribed dose of the statin, while also negatively affecting drug adherence. More than 90% of patients with SAMS can keep on taking statins over the long term and gain the full clinical benefit of statin treatment after a switch to another type of statin or a readjustment of the dose or frequency of administration. If the LDL cholesterol concentration is not adequately lowered while the patient is taking a statin in the highest tolerable dose, combination therapy is indicated.
conclusionSAMS are important adverse effects of statin treatment because they lessen drug adherence. Patients with SAMS should undergo a thorough diagnostic evaluation followed by appropriate counseling. In most cases, statins can be continued, with appropriate adjustments, even in the aftermath of SAMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.